Patent · US Active

Anti-Siglec-5 antibodies and methods of use thereof

US12258398B2 · kind B2 · utility

0Cited by

60References

34Claims

0Family size

Assignee

Alector LLC

Inventors

Patricia Culp · Oakland, US
Rashmi Bankoti · San Mateo, US
Helen LAM · Union City, US
Arnon Rosenthal · Woodside, US

Key dates

Filing date	Jul 26, 2019
Grant date	Mar 25, 2025
Priority date	—
Expiry date	Nov 5, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.